Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Incyte Corporation

Market Cap 20.86B 18.36B 16.94B 15.84B 29.68B 1,966B 30.23B 204B 78.84B 970B 78.31B 76.61B 3,374B P/E 2026 *
15.8x
P/E 2027 * 13.3x
Enterprise Value 15.88B 13.98B 12.89B 12.06B 22.59B 1,496B 23.01B 155B 60.01B 738B 59.6B 58.31B 2,568B EV / Sales 2026 *
2.82x
EV / Sales 2027 * 2.25x
Free-Float
98.11%
Yield 2026 *
-
Yield 2027 * -
1 day+3.78%
1 week+9.38%
Current month+11.92%
1 month+11.51%
3 months+19.48%
6 months+7.80%
Current year+9.62%
1 week 96.09
Extreme 96.09
109.1
1 month 92.18
Extreme 92.18
110.34
Current year 89.25
Extreme 89.25
112.29
1 year 66.83
Extreme 66.83
112.29
3 years 50.27
Extreme 50.27
112.29
5 years 50.27
Extreme 50.27
112.29
10 years 50.27
Extreme 50.27
153.15
Manager TitleAgeSince
Chief Executive Officer 58 26/06/2025
Director of Finance/CFO 57 04/05/2026
President 62 05/06/2023
Director TitleAgeSince
Chairman 59 26/06/2025
Director/Board Member 72 20/01/2015
Director/Board Member 64 20/01/2015
Date Insider Type Main position Quantity % Market Cap.
06-08Free

Director

7,753 0.0039%
06-08
FBS Associates LLC
OtherCompany 0 0%
06-08
Baker Bros. Advisors LP
FreeCompany 15,506 0.0078%
Change 5-day change 1-year change 3-year change Capi.($)
+3.78%+9.38%+56.90%+72.03% 20.86B
+1.39%+2.82%+19.69%-20.31% 62.88B
+1.31%+1.03%+54.22%+215.05% 54.54B
+8.80%+38.50%+38.50%+38.50% 38.44B
+2.63%+8.23%-52.24%-59.22% 37.17B
+1.53%+0.43%+57.96%-29.14% 29.11B
+0.41%-0.94%+128.43%-49.16% 24.2B
+1.90%+2.03%-1.20%+155.99% 16.96B
+1.03%+6.99%+69.37%+126.54% 16.6B
+2.86%+4.60%+58.58%+355.07% 13.44B
Average +2.56%+2.76%+43.02%+80.53% 31.42B
Weighted average by Cap. +2.60%+2.03%+37.03%+59.56%

Financials

2026 *2027 *
Net sales 5.63B 4.95B 4.57B 4.27B 8.01B 530B 8.16B 54.91B 21.27B 262B 21.12B 20.67B 910B 6.23B 5.48B 5.06B 4.73B 8.86B 587B 9.03B 60.77B 23.54B 290B 23.38B 22.87B 1,007B
Net income 1.38B 1.22B 1.12B 1.05B 1.97B 130B 2B 13.48B 5.22B 64.21B 5.18B 5.07B 223B 1.66B 1.46B 1.34B 1.26B 2.36B 156B 2.4B 16.16B 6.26B 77B 6.22B 6.08B 268B
Net Debt -4.98B -4.39B -4.05B -3.78B -7.09B -470B -7.22B -48.62B -18.83B -232B -18.71B -18.3B -806B -6.83B -6.01B -5.55B -5.19B -9.72B -644B -9.9B -66.65B -25.82B -318B -25.64B -25.09B -1,105B
Logo Incyte Corporation
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (84.7%); - royalties (12.4%); - income from research and cooperation agreements (2.9%).
Employees
2,844
Date Price Change Volume
24/06/26 $108.32 +3.75% 764,926
23/06/26 $104.40 +0.71% 1,670,984
22/06/26 $103.66 +5.54% 2,204,988
18/06/26 $98.22 -0.78% 4,058,623
17/06/26 $98.99 -0.76% 1,716,059
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
27
Last Close Price
104.40USD
Average target price
110.26USD
Spread / Average Target
+5.61%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INCY Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!